TEVA logo

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

26,980
Mkt Cap
$35.96B
Volume
7.36M
52W High
$33.42
52W Low
$12.47
PE Ratio
51.22
TEVA Fundamentals
Price
$31.36
Prev Close
$31.76
Open
$30.78
50D MA
$28.81
Beta
0.80
Avg. Volume
8.94M
EPS (Annual)
-$1.46
P/B
4.96
Rev/Employee
$458,660.10
Loading...
Loading...
News
all
press releases
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
JNJ heads into Q4 earnings with strong pharma and MedTech momentum, offset by Stelara biosimilar pressure and China-related headwinds.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Lifted by Harel Insurance Investments & Financial Services Ltd.
Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.9% in the 3rd quarter, according to the company in its...
MarketBeat·3d ago
News Placeholder
Wall Street Zen Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Buy
Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Sunday...
MarketBeat·3d ago
News Placeholder
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
Zacks·5d ago
News Placeholder
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·6d ago
News Placeholder
Commonwealth Equity Services LLC Acquires 122,701 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
Commonwealth Equity Services LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 75.3% during the third quarter, according to its most recent filing with the...
MarketBeat·6d ago
News Placeholder
Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High - Time to Buy?
Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 52-Week High - Here's What Happened...
MarketBeat·8d ago
News Placeholder
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
Zacks·9d ago
News Placeholder
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·9d ago
News Placeholder
Why Is TEVA Stock Rising Pre-Market Today?
Teva announced a funding agreement with Royalty Pharma of up to $500 million to advance its anti-IL-15 antibody, TEV-‘408, across its clinical programs.
Stocktwits·9d ago
<
1
2
...
>

Latest TEVA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.